Study Finds Gastroenterologist-Developed Atrantíl Safely and Effectively Manages Symptoms of Irritable Bowel Syndrome

Double-Blind, Randomized, Placebo-Controlled Study Shows Blend of Botanical Extracts Helps Manage Symptoms of Bloating and Constipation in IBS-C Patients

DALLAS--()--A new study published in the Journal of Gastroenterology and Hepatology Research proved the efficacy and safety of the blend of botanical extracts used in plant-based digestive health reliever Atrantíl [ah-tran-teal] to effectively manage symptoms of patients suffering from Irritable Bowel Syndrome with constipation (IBS-C). The two-week, double-blind, randomized, placebo-controlled pilot study found overall quality of life scores improved by 90 percent, with constipation improving by 33 percent and bloating by 59 percent.

“As a 16-year veteran of medicine and board-certified gastroenterologist, I see firsthand the discomfort and interference that IBS causes patients in their daily lives,” said Dr. Kenneth Brown, co-founder of Atrantíl. “Following eight years of formulation, scientific testing and development, we’ve worked hard to create Atrantíl, a unique supplement that can help alleviate bloating, abdominal discomfort and constipation where symptoms actually start – in the small bowel – without the use of harsh pharmaceuticals. For the seven to 20 percent of the population experiencing IBS around the world this is a major breakthrough that can help them finally feel relief.”

Participants of the study ranged in age from 23-57, were diagnosed with IBS-C at least six months prior to enrollment, and had a history of uncontrolled symptoms of constipation and bloating. The study provided participants with both Atrantíl and placebos to effectively measure improved scores of IBS symptoms related to bloating, abdominal discomfort and constipation. Those who took Atrantíl showed 70 percent greater improvement than those that were given placebos. Participants reported no adverse events during the two-week period.

Atrantíl is a scientifically crafted nutraceutical made up of botanical extracts, including Quebracho, Conker Tree and Mentha balsamea Willd. These ingredients were specifically designed to work in perfect synergy in the small bowel in order to create a sterile environment and alleviate bloating, abdominal discomfort and constipation. Available without a prescription, Atrantíl is free of milk, eggs, peanuts, soy and shellfish, and touts a patent-pending combination of Certified Gluten Free, vegan and non-GMO ingredients and botanical extracts. Created to leave users feeling light and free, Atrantíl retails for $39.95/60 capsules (275 mg; 30-day supply).

To learn more and read the full study, visit the Journal of Gastroenterology and Hepatology Research website at www.ghrnet.org.

Atrantíl is doctor recommended and available online and at select distributors. For more information or to purchase Atrantíl, visit www.atrantil.com.

About Atrantíl

In 2012, Kenneth Brown, M.D., and Brandi Scott-Hoy, M.A., formed the parent company of Atrantíl, KBS Research, after being inspired to develop a new method of treating digestive woes in the small bowel and promote overall digestive health. Following eight years of research, formulation, scientific testing and development, the pair launched Atrantíl in 2015, offering a new, unparalleled way to achieve digestive health relief. Atrantíl is clinically proven to address bloating, abdominal discomfort and constipation at their source and is a nutraceutical unlike antibiotics and probiotics. It is scientifically crafted using a patent-pending formula comprised of botanical extracts and Certified Gluten Free and non-GMO ingredients in a capsule format and available without a prescription. To learn more, please visit www.Atrantil.com, or follow Atrantíl on Facebook and Twitter.

Contacts

Rachel Kay Public Relations
Malena Whetro, 858-243-4761
Media@Atrantil.com

Release Summary

Journal of Gastroenterology and Hepatology Research study proved the efficacy and safety of botanical extracts used in Atrantíl to effectively manage symptoms of patients with IBS-C.

Contacts

Rachel Kay Public Relations
Malena Whetro, 858-243-4761
Media@Atrantil.com